{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:08:51Z","timestamp":1784326131836,"version":"3.55.0"},"reference-count":33,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The development and implementation of new targeted and immunotherapeutic approaches in the treatment landscape of mantle cell lymphoma have already improved therapeutic options especially for refractory or relapsed disease. Regarding first\u2010line therapy, treatment strategies including novel agents are under investigation. In transplant\u2010eligible patients, a combined ibrutinib\u2010containing immunochemotherapy induction followed by ASCT was shown to be superior compared to the chemotherapy regimen +\/\u2212 ASCT. Thus, we consider the addition of ibrutinib to first\u2010line therapy in younger MCL patients a new standard of care. For the group of older MCL patients ineligible for high\u2010dose therapy and ASCT, several targeted therapy approaches have been investigated in different studies in combination with immunochemotherapies or as single agents +\/\u2212 other targeted therapies with promising results. This review summarizes the current standard of care for first\u2010line treatment of mantle cell lymphoma, highlighting the implementation of targeted treatment strategies, especially BTKi, in initial treatment strategies.<\/jats:p><jats:p><jats:bold>Trial Registration:<\/jats:bold> ClinicalTrials.gov identifier: NCT06482684<\/jats:p>","DOI":"10.1002\/hon.70073","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T17:52:22Z","timestamp":1750009942000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["First Line Therapy in Mantle Cell Lymphoma\u2014The Role of BTKi in the Initial Treatment of Transplant\u2010Eligible and \u2010Ineligible Patients"],"prefix":"10.1002","volume":"43","author":[{"given":"E.","family":"Silkenstedt","sequence":"first","affiliation":[{"name":"Department of Medicine III LMU Hospital  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Department of Medicine III LMU Hospital  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,15]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx223"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11096"},{"key":"e_1_2_7_4_1","unstructured":"S. H.Swerdlow E.Campo N. L.Harris eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours rev 4th ed. Vol.2.2."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.63.8387"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01780"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(21)00195-2"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14241"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1200920"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000712"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.19.6121"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1701769"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02698"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00184-3"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200735"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201441"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-212973"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01977-y"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-797019"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-628792"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779736"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025563"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206931"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30685-5"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(16)30185-5"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61763-2"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011305"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01294"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2201817"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200290"},{"key":"e_1_2_7_33_1","unstructured":"J. M.Michael Wang D.Belada Y.Song et\u00a0al. \u201cAcalabrutinib Plus Bendamustine and Rituximab in Untreated MCL: Results From the Phase 3 ECHO Trial \u201d EHA Library; 4136515; LB3439 (2024)."},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199710"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:37:17Z","timestamp":1760557037000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":33,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/hon.70073"],"URL":"https:\/\/doi.org\/10.1002\/hon.70073","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2025-03-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70073"}}